Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment-Reference-Cited by-同舟云学术

Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment

Published:2014-01-01 Issue:1 Volume:150 Page:25
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Fichel Fanny¹,Barbe Coralie²,Joly Pascal³,Bedane Christophe⁴,Vabres Pierre⁵,Truchetet François⁶,Aubin François⁷,Michel Catherine⁸,Jegou Juliette⁹,Grange Florent¹,Antonicelli Frank¹⁰,Bernard Philippe¹

Affiliation:

1. Department of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France

2. Clinical Research Unit, Reims University Hospital, Reims, France

3. Department of Dermatology, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandy, Rouen, France

4. Department of Dermatology, Limoges University Hospital, Limoges, France

5. Department of Dermatology, Dijon University Hospital, Dijon, France

6. Department of Dermatology, Beauregard Hospital, Thionville, France

7. Department of Dermatology, Besançon University Hospital, Besançon, France

8. Department of Dermatology, Mulhouse Hospital, Mulhouse, France

9. Department of Dermatology, Chalons en Champagne Hospital, Chalons en Champagne, France

10. Laboratory of Dermatology, Faculty of Medicine of Reims, University of Champagne-Ardenne, Reims, France

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal monitoring of enzyme-linked immunosorbent assay for NC16A-BP180 or BP230 antibodies as a biomarker of disease activity in pemphigoid: A systematic review;JAAD Reviews;2024-09

2. Eosinophil and Monocyte Counts as Hematological Markers for Response to Tetracyclines for Treating Bullous Pemphigoid;Turkish Journal of Dermatology;2024-07-22

3. Unmet needs in treating itch: reaching beyond eczema;Journal of Dermatological Treatment;2024-06-13

4. Immunobullous Diseases;Rook's Textbook of Dermatology;2024-03-19

5. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT;Advances in Therapy;2024-03-05